Literature DB >> 18022932

Human CMV immediate-early enhancer: a useful tool to enhance cell-type-specific expression from lentiviral vectors.

Ina Gruh1, Stephanie Wunderlich, Monica Winkler, Kristin Schwanke, Jennifer Heinke, Ulrike Blömer, Arjang Ruhparwar, Bettina Rohde, Ren-Ke Li, Axel Haverich, Ulrich Martin.   

Abstract

BACKGROUND: Lentiviral vectors are attractive delivery tools for gene therapy, especially in terminally differentiated target cells. While restriction of gene expression to specific cell populations is of particular importance, highly efficient cell-type-specific gene expression after viral gene transfer so far has been hampered by low levels of transgene expression.
METHODS: Addressing this problem, we have integrated the human cytomegalovirus (CMV) immediate-early enhancer into an 'advanced' generation lentiviral vector. Expression cassettes with the reporter gene green fluorescent protein (GFP), combined with the woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) under control of a ubiquitous phosphoglycerate kinase (mouse PGK), cardiomyocyte- (human atrial natriuretic factor (ANF), human ventricular myosin light chain (MLC2v)), or type II alveolar epithelial cell (AT-2)-specific human surfactant protein C (SP-C) promoter, were introduced. As insertion of an enhancing element can interfere with the promoter's specificity, expression levels conferred by our enhancer/promoter constructs were evaluated in target and non-target cells.
RESULTS: Transduction of target cells with human CMV enhancer containing lentiviral vectors resulted in a multiple-log increase in GFP expression compared to corresponding vectors lacking the human CMV enhancer. In the case of the ANF, the MLC2v, and the SP-C promoters, tissue-specific reporter gene expression in cardiomyocytes and in lung AT-2 cells was maintained, as expression in non-target cells increased only up to 7-fold.
CONCLUSIONS: The results of this study indicate that lentiviral vectors with the human CMV enhancer conferring efficient cell-type-specific gene expression may be useful tools for gene therapy purposes or cell tracing, e.g. to analyze stem cell differentiation in transplantation and co-culture settings. (c) 2007 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18022932     DOI: 10.1002/jgm.1122

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  19 in total

1.  Serotype-dependent transduction efficiencies of recombinant adeno-associated viral vectors in monkey neocortex.

Authors:  Annelies Gerits; Pascaline Vancraeyenest; Samme Vreysen; Marie-Eve Laramée; Annelies Michiels; Rik Gijsbers; Chris Van den Haute; Lieve Moons; Zeger Debyser; Veerle Baekelandt; Lutgarde Arckens; Wim Vanduffel
Journal:  Neurophotonics       Date:  2015-10-01       Impact factor: 3.593

2.  CMV enhancer-promoter is preferentially active in exocrine cells in vivo.

Authors:  D B Vasey; S G Lillico; H M Sang; T J King; C B A Whitelaw
Journal:  Transgenic Res       Date:  2008-12-16       Impact factor: 2.788

3.  CMV enhancer may not be suitable for tissue-specific enhancement of promoters in cancer gene therapy.

Authors:  Jing Jia; Shuzhi Zhang; Zhenyu Jia; Jiang Cao
Journal:  Cancer Gene Ther       Date:  2019-05-27       Impact factor: 5.987

Review 4.  Viral expression cassette elements to enhance transgene target specificity and expression in gene therapy.

Authors:  Sara Kathleen Powell; Ricardo Rivera-Soto; Steven James Gray
Journal:  Discov Med       Date:  2015-01       Impact factor: 2.970

5.  MicroRNA target sites as genetic tools to enhance promoter-reporter specificity for the purification of pancreatic progenitor cells from differentiated embryonic stem cells.

Authors:  Ulf Diekmann; Matthias Elsner; Jan Fiedler; Thomas Thum; Sigurd Lenzen; Ortwin Naujok
Journal:  Stem Cell Rev Rep       Date:  2013-10       Impact factor: 5.739

6.  Combined paracrine and endocrine AAV9 mediated expression of hepatocyte growth factor for the treatment of renal fibrosis.

Authors:  Stephanie Schievenbusch; Ingo Strack; Melanie Scheffler; Roswitha Nischt; Oliver Coutelle; Marianna Hösel; Michael Hallek; Jochen W U Fries; Hans-Peter Dienes; Margarete Odenthal; Hildegard Büning
Journal:  Mol Ther       Date:  2010-04-27       Impact factor: 11.454

7.  Restricted transgene expression in the brain with cell-type specific neuronal promoters.

Authors:  Aurélie Delzor; Noelle Dufour; Fanny Petit; Martine Guillermier; Diane Houitte; Gwennaelle Auregan; Emmanuel Brouillet; Philippe Hantraye; Nicole Déglon
Journal:  Hum Gene Ther Methods       Date:  2012-08-30       Impact factor: 2.396

8.  A potassium leak channel silences hyperactive neurons and ameliorates status epilepticus.

Authors:  Deblina Dey; Veit-Simon Eckle; Iuliia Vitko; Kyle A Sullivan; Zofia M Lasiecka; Bettina Winckler; Ruth L Stornetta; John M Williamson; Jaideep Kapur; Edward Perez-Reyes
Journal:  Epilepsia       Date:  2013-12-02       Impact factor: 5.864

9.  Desmin-regulated lentiviral vectors for skeletal muscle gene transfer.

Authors:  Gillian E Talbot; Simon N Waddington; Olivia Bales; Rose C Tchen; Michael N Antoniou
Journal:  Mol Ther       Date:  2009-11-24       Impact factor: 11.454

10.  Posttranscriptional regulatory elements enhance antigen expression and DNA vaccine efficacy.

Authors:  Jing Sun; Dingfeng Li; Yanling Hao; Yuwei Zhang; Wenling Fan; Jingjing Fu; Yunzhang Hu; Yong Liu; Yiming Shao
Journal:  DNA Cell Biol       Date:  2009-05       Impact factor: 3.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.